AbbVie is facing a major challenge to its business in the coming years with the loss of patent protection for immunology behemoth Humira (adalimumab), which saw sales plunge by a third to $11.1 ...

AbbVie and Alphabet spin-out Calico Life Sciences have agreed to fund their seven-year-old partnership seeking treatments for diseases of ageing with another $500 million apiece. The collaboration ...

The Alzheimer’s Drugs Market is anticipated to experience a compound annual growth rate (CAGR) of approximately 20% over the ...

A company expected to fare well during this time is Eli Lilly, with revenue forecast to improve by 165% in 2030. This will largely be driven by the company’s glucagon like peptide-1 receptor agonist ...

The Hong Kong-listed firm is advancing its pipeline using an mRNA system it says can compete with the industry’s best.

AbbVie partners with IGI Therapeutics for ISB 2001, a potential cancer and autoimmune therapy. Read more here.

AbbVie remains strong long-term performer, offering a solid dividend yield and robust revenue growth despite share price dips ...

IGI Therapeutics SA, a wholly-owned subsidiary of Ichnos Glenmark Innovation (IGI)—an alliance between Glenmark Pharma and Ichnos Sciences Inc.—has signed an exclusive licensing agreement with AbbVie ...

The global modified release formulations market is set for continued expansion between 2025 and 2035, with its size projected to rise from USD 282.1 billion to approximately USD 524.7 billion, ...

The global Monoclonal Antibodies Market was valued at USD 186 Billion in 2021 and is projected to exhibit a CAGR of 12% from ...

This article emphasizes the vital role of patient involvement in healthcare, illustrating how patient engagement can improve treatment outcomes, build trust, drive innovation, and reduce costs.